Mitsubishi UFJ Asset Management’s ProQR Therapeutics PRQR Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-39,544	Closed	-$36K	–	1190
2022 Q1	$36K	Buy	39,544 +2,431	+7%	+$8.14K	﹤0.01%	1143
2021 Q4	$300K	Sell	37,113 -10,542	-22%	-$80.3K	﹤0.01%	1011
2021 Q3	$399K	Buy	47,655 +1,286	+3%	+$8.4K	﹤0.01%	972
2021 Q2	$313K	Buy	+46,369	New	+$299K	﹤0.01%	1034
2019 Q4	–	Sell	-12,018	Closed	-$69K	–	1031
2019 Q3	$69K	Buy	12,018 +1,483	+14%	+$11.8K	﹤0.01%	936
2019 Q2	$96K	Buy	10,535 +1,979	+23%	+$23.3K	﹤0.01%	921
2019 Q1	$119K	Buy	8,556 +1,585	+23%	+$23.7K	﹤0.01%	861
2018 Q4	$124K	Buy	+6,971	New	+$128K	﹤0.01%	816

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Mitsubishi UFJ Asset Management's PRQR Position: Q2 2022 in Review

Mitsubishi UFJ Asset Management sold out of ProQR Therapeutics (PRQR) in Q2 2022, closing a stake of 39,544 shares — an estimated $36K sold.

Mitsubishi UFJ Asset Management first reported a position in PRQR in Q4 2018 and held it in 8 quarters. The position peaked at $399K in Q3 2021. 51 funds tracked by Wall St. Rank hold PRQR as of Q2 2022.

Mitsubishi UFJ Asset Management reported no remaining ProQR Therapeutics position as of Q2 2022 after selling out during the quarter.
Mitsubishi UFJ Asset Management sold 39,544 ProQR Therapeutics shares in Q2 2022, an estimated $36K.
Mitsubishi UFJ Asset Management first reported a position in ProQR Therapeutics in Q4 2018 and held it in 8 quarters.
Mitsubishi UFJ Asset Management's ProQR Therapeutics position peaked at $399K in Q3 2021.
51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2022.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2022, filed 4 Aug 2022.